The deck is stacked against the avg Andres...Just trying to beat the odds.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No it doesn't.
Semantics, for sure. The trial has ended. The data was locked. The data was presented... twice.
I get it... but then again, given what we know about DCVax-L via trial data presentations, I don't.
I understand the frustrations and irritations regarding expectations (not promises, imho) that NWBO set EXPLICITLY but did not deliver... without ever addressing the issue... and simply moved on to another different milestone. Also, there were a number expectations that retail erroneously set by misinterpreting 'signals' and tea-leaf reading.
But, despite all of the missed expectations, the data is clear: DCVax-L works. One would have to concluded the LP has more invested in NWBO, more to loose and more to gain from the success of DCVax-L. This, in addition to her 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing, more than suggests to me that any missed expectations is not intentional or due to incompetence on her part but is twist of circumstances out of her control, forcing her to adjust.
Vator, I am not trivializing your valid concerns, frustrations and disappointments. I have felt them too. But the trial has ended. The data from the phase3 trial is what we expected. This is not a time to be weary or overcome with impatience. It would be a damn shame for NWBO longs to fight for damn near 10 years to hold on to NWBO through all the bullshit only to give up just before the gains.
Stay strong....
This is the way wall street works: Frustrate you into selling your hard-earned, deserved shares (that you have held through pain and sacrifice) for peanuts. This is a mistake. There's a reason why wall-street refers to retail as "dumb money", no offense to you and other frustrated longs.
I'll be damned if I held my shares for 10 years and through the Woodford debacle only to sell AFTER the data has been presented and light can be seen at the end of the tunnel but BEFORE the stock appreciates. I will not allow Wallstreet to make significant $$$ that was meant for me!
I don't know why one feels dupped given the data presented.
2.50 my @zz, lol! If anyone wants to buy NWBO, that means they believe there is ample indication that DCVax-L works. If DCVax-L works-- which we know it does based on recent presentations/data-- why would anyone sell at a measly $2.50 when Direct is not yet in the picture or the treatment is not yet SOC.
If DCVAX-L works and it becomes SOC for all tumor-based cancers, selling at $2.50 seems insane...
But what do I know.
No. I have read enough to understand what you are saying... and what you are saying is erroneous. Have a wonderful day too.
Here is what you said: "The PIP trial was for a large part the achievement of a third-party consultancy firm".
Here is the quote you used to support what you said:
Hear! Hear!
Let me rephrase:
So, based on the quote you provided:
1. Northwest Biotherapeutics worked with expert consultants for months to develop a PIP tailored for application of DCVax-L;
2. Northwest Biotherapeutics submitted its proposed PIP to the MHRA in February 2022, and has been going through the regulatory review process since then;
3. Northwest Biotherapeutics received final approval of the PIP from the MHRA....
But you conclude all of this was not the achievement of NWBO for DCVAX-L but "was for a large part (your emphasis) the achievement of a third-party consultancy firm".
Do you realize the quote you used to support your statement makes the opposite case?
So you present the following quote (red bold and underlining added for emphasis):
Correction noted. I agree. It's much, much worst than I stated.
Adam Feuerstein and his ilk has ignored every positive accomplishment NWBO has made to focus exclusively on even potential/speculative issues for the past decade. Obviously, you are not Feuerstein, but the way you ignored the spectacularly positive primary endpoint data is eerily similar.
Feuerstein and his ilk (as well as your focus on the potential negative while ignoring the spectacularly positive) are irrelevant. The plane has left the runway.
Again, thanks for finally acknowledging the primary OS, "THE" gold standard, endpoints were met in the DCVax-L p3 trial.
It's just strange that in most of your posts, you list every "potential" issue (even non-existent ones) regarding the DCVax trial, lol. At the same time, you tend to avoid the huge positives-- like the primary endpoints. Even when I pressed (after multiple times), you finally blurt out "I do" but quickly turn the focus on a speculative, alleged secondary endpoint failure. It seems that you often side-step or ignore spectacularly positive info to focus on a what could be a potential issue. Maybe I got it wrong.
But thanks for acknowledging the primary OS, "THE" gold standard, endpoints were met in the DCVax-L p3 trial.
Cheers...
No need to cry if you know what you hold.
Based on your post, you've seen the trial results. You admit that manipulators are beating the hell out of the stock. So the only problem, as you defined it, is the company has not responded to the manipulation.
Why would LP not respond? Due to her investment into NWBO/DCVax in terms of financial capital, time and effort, legacy, etc, she has more of an incentive to respond than you or anyone on this mb does? Keep in mind, she
has "over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing".
LP WILL respond... spectacularly, imho.
We need to calm down and just wait. To long-time investors who've been here when the data was nowhere near as solid as it is now, this is the easy part.
Absolute BS!
So, Bill, you concur that the primary OS-related (i.e., "THE" gold standard) endpoints were met, right?
So, Bill, you concur that the primary OS-related (i.e., "THE" gold standard) endpoints were met, right?
So, Bill, you concur that the primary OS-related (i.e., "THE" gold standard) endpoints were met, right?
Yep! Then why is this poster saying the endpoints were pfs related? FUD!
We know that.... and he knows it too; Hence, my question, WTF?!
WTF?! Did you read the trial info or listen to the presentations?! The primary endpoint is based on pfs?! Please stop the bs!
LMAO...
Lol... You have to know that position is absolute bs.
He's denizen of the Twitter universe? What a ridiculously foolish statement.
LMAO... I do that every now and then... somehow.
Nuff said...
Could you expound on this point a bit?
Lol... We must be close!
Ridiculous...
Just like the DCVax trial was never expected to end?
Hear! Hear!
I don't think it will take 2.5 years for FDA approval, but I am interested why you think so. How long are you estimating it will take NWBO to write/submit the BLA (assuming it isn't done already)? What is your estimate of time FDA will require to review it and make approval decision (assuming NWBO hasn't been working with FDA-- i.e. rolling review-- all along)? Just curious.
No it was an official email sent from Northwest Biotherapeutics <dinnes@nwbio.com>.
AF's cabal will continue their deeds even after approval. The won't stop.
Thx Captain. That sounds reasonable. With DCVax approval and the combo patent, good times are ahead.